Dow Up0.35% Nasdaq Down0.02%

Access Pharmaceuticals Inc. (ACCP)

0.33 Down 0.02(5.71%) Aug 20, 3:38PM EDT
ProfileGet Profile for:
Access Pharmaceuticals Inc.
4848 Lemmon Avenue
Suite 517
Dallas, TX 75219
United States - Map
Phone: 214-905-5100
Fax: 214-905-5101

Index Membership:N/A
Industry:Drug Manufacturers - Other
Full Time Employees:6

Business Summary 

Access Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the development of novel therapeutics for the treatment of cancer and supportive care of cancer patients. Its marketed product includes MuGard for the management of oral mucositis. The company’s products under development comprise ProctiGard for the management of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region; LexaGard for the treatment of conditions of the upper gastrointestinal tract, including Barrett’s esophagus and esophagitis; CobOral, a preclinical nanopolymer oral drug delivery technology based on the natural vitamin B12 oral uptake mechanism; and CobaCyte, a preclinical nanopolymer that constructs to deliver anti-cancer drug to tumors protecting normal tissues. Access Pharmaceuticals, Inc. is based in Dallas, Texas.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Access Pharmaceuticals Inc.

Key Executives 
Mr. Jeffrey B. Davis , 51
Chief Exec. Officer, Pres, Acting Chief Financial Officer, Principal Accounting Officer, Sec., Treasurer and Director
Dr. David P. Nowotnik Ph.D., 65
Christine Berni ,
Director of Investor Relations
Mr. Anthony Mottola ,
VP of Managed Care & Market Access
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders